The authors of a recent report point to a “conspicuous absence” of the term CKD from the 2019 EULAR/ERA lupus nephritis guidelines. Chronic kidney disease (CKD) is a missing concept in lupus nephritis guidelines, according to a review article.
Logramos reter a inflmación dos quistes, o que retrasa as súa progresión no ril
elprogreso.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from elprogreso.es Daily Mail and Mail on Sunday newspapers.
Verbal disagreement in South Tahoe leads to vandalism, arrest
tahoedailytribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tahoedailytribune.com Daily Mail and Mail on Sunday newspapers.
May 06, 2021
published at 7:30 AMglobenewswire
PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial
GlobeNewswire
May 06, 2021
BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4
th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d Hebron in Barcelona.
Patients with advanced solid tumors are currently being enrolled in 3 Spanish sites for a Phase I clinical study: the Hospital Universitari Vall d Hebron in Barcelona, and the Hospital Universitario HM Sanchinarro and Hospital Fundación Jimenez Diaz in Madrid.
(0)
BARCELONA, Spain, May 06, 2021 (GLOBE NEWSWIRE) Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4
th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d Hebron in Barcelona.
Patients with advanced solid tumors are currently being enrolled in 3 Spanish sites for a Phase I clinical study: the Hospital Universitari Vall d Hebron in Barcelona, and the Hospital Universitario HM Sanchinarro and Hospital Fundación Jimenez Diaz in Madrid.